FORTIS902.00

Fortis Healthcare Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHMEDANTAAUROPHARMALUPINALKEMLAURUSLABSMANKINDMcap ₹68,097 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
FORTIS
FY26
APOLLOHOSP
FY26
MAXHEALTH
FY26
MEDANTA
FY26
Peer
Median
Valuation — at last close
P/E65.36×65.86×69.66×70.35×69.66× -6%
P/B6.70×12.82×9.36×9.83×9.83× -32%
EV/EBITDA33.84×34.95×46.08×43.75×43.75× -23%
Market Cap₹68,097 Cr₹1.28L Cr₹1.01L Cr₹39,148 Cr₹1.01L Cr -32%
Growth
Revenue CAGR 3Y13.17%14.94%22.43%17.85%17.85% -26%
Revenue CAGR 5Y17.76%19.03%27.30%23.16% -23%
Net Income CAGR 3Y18.91%33.35%9.34%19.33%19.33% -2%
Revenue YoY (latest Q)17.46%20.56%16.70%26.50%20.56% -15%
Net Income YoY (latest Q)2.26%38.41%4.87%-1.09%4.87% -54%
Profitability
EBITDA Margin22.84%14.94%26.79%20.84%20.84% +10%
Net Income Margin11.66%7.94%17.23%12.56%12.56% -7%
Return on Common Equity10.25%19.47%13.42%13.97%13.97% -27%
Return on Capital Employed11.81%18.41%11.94%13.20%13.20% -11%
Return on Assets6.67%9.02%8.37%9.38%9.02% -26%
Credit & Quality
Total Debt/Equity0.28×0.57×0.32×0.30×0.32× -12%
Interest Coverage5.20×6.44×7.64×8.80×7.64× -32%
Scale — latest FY
Revenue / Total Income₹9,128 Cr₹25,229 Cr₹8,373 Cr₹4,410 Cr₹8,373 Cr +9%
Net Income₹1,064 Cr₹2,003 Cr₹1,442 Cr₹554 Cr₹1,442 Cr -26%
Total Assets₹15,966 Cr₹22,197 Cr₹17,231 Cr₹5,905 Cr₹17,231 Cr -7%
EPS₹13.8₹135.04₹14.83₹20.71₹20.71 -33%
Book Value per Share₹134.69₹693.64₹110.43₹148.29₹148.29 -9%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.